Oncology PracticeNational lung cancer screening guidelines may miss younger African American individuals at high riskOctober 19, 2020Lung Cancer
Oncology PracticeClinical factors and treatment tied to COVID-19 mortality in cancer patientsOctober 8, 2020Patient & Survivor CareCNS/Brain CancerCOVID-19 UpdatesGastroenterologyGenitourinary CancerGynecologic CancerHead & Neck/Thyroid Cancers
Oncology PracticeFDA OKs combination immunotherapy for first-line mesothelioma treatmentOctober 5, 2020Lung Cancer
Oncology PracticeThe scope of under- and overtreatment in older adults with cancerOctober 1, 2020Patient & Survivor CareBreast CancerCNS/Brain CancerGastroenterologyGenitourinary CancerGynecologic CancerHead & Neck/Thyroid Cancers
Oncology PracticeCancer disparities: One of the most pressing public health issuesSeptember 30, 2020Patient & Survivor CareBreast CancerCNS/Brain CancerGastroenterologyGenitourinary CancerGynecologic CancerHead & Neck/Thyroid Cancers
Oncology PracticeGlobal stomach cancer deaths decline as colorectal cancer deaths stagnate, riseSeptember 25, 2020GastroenterologyBreast CancerLung CancerGenitourinary CancerGI OncologyGastrointestinal Cancer
Oncology PracticeLorlatinib: Another first-line option for ALK-positive NSCLC?September 22, 2020Lung Cancer
Oncology PracticeNo benefit with postoperative radiotherapy in stage IIIAN2 NSCLCSeptember 20, 2020Lung Cancer
Oncology PracticeSurvey quantifies COVID-19’s impact on oncologySeptember 20, 2020COVID-19 UpdatesBreast CancerCNS/Brain CancerDLBCLFollicular LymphomaLung CancerLeukemia, Myelodysplasia, Transplantation
Oncology PracticeCOVID-19 prompts ‘democratization’ of cancer trialsSeptember 16, 2020COVID-19 UpdatesPatient & Survivor CareCNS/Brain CancerGastroenterologyGenitourinary CancerGynecologic CancerHead & Neck/Thyroid Cancers
Oncology PracticeThe march of immunotherapy continues at ESMO 2020September 15, 2020ImmunotherapyGenitourinary CancerGastroenterologyLung CancerPatient & Survivor CareRenal Cell CarcinomaPractice Management
Oncology PracticePralsetinib: Second drug for RET+ NSCLC approved in U.S.September 8, 2020Lung Cancer
